Menu
Recruiting NCT05384808

Canine-assisted Psychotherapy Motivation Alliance

No phase Interventional Motivation Alliance, Therapeutic

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Standard Psychotherapy, Canine-assisted psychotherapy with dog actively integrated., Canine-assisted psychotherapy with dog passively integrated..
Who it may be relevant to
Registry conditions: Motivation, Alliance, Therapeutic. Basic parameters: 9 years — 17 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Switzerland
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effects of the Inclusion of a Dog in Psychotherapy on Children's Alliance and Treatment Motivation

Overview

The aim of the study is to investigate the needed extent and the way a dog is integrated into psychotherapeutic interventions for them to be motivating and alliance building for children and adolescents with psychiatric disorders aged 9 to 17 years old. Specifically, we want to elaborate if the dog needs to be integrated into the therapy in a form that it is part of the therapeutic context or if the presence of the dog without being part of the therapeutic context per se is beneficial.

Interventions

  • Behavioral Standard Psychotherapy
    Participants receive a standard psychotherapy session with no dog being present.
  • Behavioral Canine-assisted psychotherapy with dog actively integrated.
    A dog is present and actively integrated into the therapeutic narrative.
  • Behavioral Canine-assisted psychotherapy with dog passively integrated.
    A dog is present but not actively integrated into the therapeutic narrative.

Primary outcome measures

  • Therapeutic alliance of patients [Time frame: 9 weeks]
  • Motivation of patients [Time frame: 9 weeks]
Secondary outcome measures (2)
  • Treatment satisfaction of patients [Time frame: 4 weeks]
  • Number of missed sessions [Time frame: 5 weeks]

Eligibility criteria

Inclusion Criteria for children and adolescents: :

  • Age between 9 and 17 years
  • Children are seeing the therapist for the first time
  • Basic knowledge of child and parents in either German or English to be able to fill in questionnaires
  • Informed consent given by legal guardian
  • Positive or neutral attitude towards dogs

Exclusion Criteria for children and adolescents: :

  • acute psychosis; early childhood autism
  • diagnosed developmental disorder or intellectual delay; if not diagnosed, exclusion when questionnaires cannot be completed due to development level
  • fear of dogs
  • allergic reactions to dogs
  • reported aggressive behavior towards animals in the past

Inclusion criteria for therapists:

  • working with an own therapy dog
  • completed therapy training or if not completed far advanced therapy training under supervision
  • working with children and adolescents aged 9 to 17 years

Exclusion criteria for therapists:

  • not working with an own therapy dog
  • no completed or far advanced therapy training
  • not working with children and adolescents aged 9 to 17 years

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Switzerland · 1 center
  • University of Basel — Basel

Publications

  • Arnskotter W, Martin S, Walitza S, Hediger K. Effects of including a dog on treatment motivation and the therapeutic alliance in child and adolescent psychotherapy: study protocol for a randomized controlled trial. Trials. 2024 Jan 5;25(1):26. doi: 10.1186/s13063-023-07854-4. PMID 38183121

Identifiers

NCT: NCT05384808 · 2022-00304

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗